Three insights:
1. Yutiq is an FDA-approved, three-year micro-insert for the treatment of chronic, non-infectious posterior segment uveitis.
2. Yutiq utilizes EyePoint’s Durasert drug delivery technology. It contains 0.18 milligrams of fluocinolone acetonide, designed to release consistently for up to 36 months.
3. In conjunction, the company launched EyePoint Assist, a program to ensure eligible patients in need of financial assistance have access to Yutiq.
More articles on improving performance:
How hospitals will handle outpatient competition & disruption in 2019 — 5 takeaways
5 must-read articles for the ASC industry this week: Jan. 25-Feb. 1
University Hospital renames outpatient facility — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
